scispace - formally typeset
G

Go Wakabayashi

Researcher at Keio University

Publications -  228
Citations -  5189

Go Wakabayashi is an academic researcher from Keio University. The author has contributed to research in topics: Transplantation & Hepatectomy. The author has an hindex of 37, co-authored 218 publications receiving 4018 citations.

Papers
More filters
Journal ArticleDOI

Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos).

Yasuhisa Mori, +59 more
TL;DR: It is confirmed that percutaneous transhepatic gallbladder drainage should be considered the first alternative to surgical intervention in surgically high‐risk patients with acute cholecystitis.
Journal ArticleDOI

Tokyo Guidelines 2018 management bundles for acute cholangitis and cholecystitis

Toshihiko Mayumi, +59 more
TL;DR: Critical parts of the bundles in TG18 include the diagnostic process, severity assessment, transfer of patients if necessary, and therapeutic approach at each time point should improve the prognosis of acute cholangitis and cholecystitis.
Journal ArticleDOI

What has changed after the Morioka consensus conference 2014 on laparoscopic liver resection

TL;DR: The most important message from the ICCLLR is to protect patients from this new surgical procedure, and the online prospective registry system including items to calculate the difficulty score has been created in Japan after the ICC LLR for the safe development of LLR.
Journal ArticleDOI

Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat

TL;DR: The data demonstrated that the production of IL-1 and TNF increases in hepatic I-R injury and that pretreatment with IL- 1ra protects the liver from ischemic insult, indicating an important role for IL-2 in I- R injury.
Journal ArticleDOI

Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation.

TL;DR: The experience has shown the feasibility of controlling rejection and other complications in adult ABO-incompatible liver transplantation under intraportal infusion therapy under intraported infusion therapy.